Fig. 5

C-Myc activation reduced miR-192-5p expression in HCC. a RT-qPCR analysis of miR-192-5p in murine oncogene-induced HCC samples and the corresponding liver controls. RNAs from 3 to 5 mice for each group were used. b RT-qPCR analysis of MYC and miR-192-5p in HCC cell lines (Huh7, HLE, HLF and HepG2) transfected with Ctrl or MYC overexpressing plasmids, as well as with Ctrl or MYC siRNAs, respectively. c Dual-luciferase assays for different miR-192-5p promoter fragments in HLE, HLF and HuH7 cells. d Dual-luciferase assay using miR-192-5p promoter (− 266 nt, + 186 nt) in HLE, HLF and HuH7 cells transfected with Ctrl or MYC overexpressing plasmids, and with Ctrl or MYC siRNAs, respectively. e Western blotting analysis for p53 and c-Myc, and RT-qPCR analysis for miR-192-5p in HepG2 treated with Nutlin-3a (10uM) and/or transfected with MYC. f miR-192-5p expression levels were shown in c-Myc activation group and c-Myc non-activation group defined in Supplementary Fig. S6c-d in two cohorts. In Cohort 2, mir-192 expression levels were further shown in subgroups with different status of p53 mutation, mir-192 promoter methylation and c-Myc activation. Student t-test was performed. *, p < 0.05